Adagene Investor Relations Material
Latest events
Q4 2024
24 Mar, 2025
Q2 2024
25 Jul, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adagene Inc
Access all reports
Adagene Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company utilizes its proprietary technology platforms, including its Dynamic Precision Library (DPL) and SAFEbody technology, to engineer therapeutic antibodies with unique functional epitopes. These technologies enable the development of innovative monoclonal antibodies that target various cancers, aiming to improve both safety and efficacy. Adagene's product pipeline includes several candidates in various stages of clinical and preclinical development. The company is actively engaged in both mono and combination therapies, exploring new approaches to treat solid tumors and other cancer types.The company is headquartered in Suzhou, China, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ADAG
Country
🇺🇸 United States